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ABSTRACT
ObjeCtive
To evaluate the frequency, validity, and relevance of 
statistically significant (P<0.05) sex-treatment 
interactions in randomized controlled trials in 
Cochrane meta-analyses.
Design
Meta-epidemiological study.
Data sOurCes
Cochrane Database of Systematic Reviews (CDSR) and 
PubMed.
eligibility Criteria fOr stuDy seleCtiOn
Reviews published in the CDSR with sex-treatment 
subgroup analyses in the forest plots, using data from 
randomized controlled trials.
Data extraCtiOn
Information on the study design and sex subgroup 
data were extracted from reviews and forest plots that 
met inclusion criteria. For each statistically significant 
sex-treatment interaction, the potential for biological 
plausibility and clinical significance was considered.
results
Among the 41 reviews with relevant data, there were 
109 separate treatment-outcome analyses (“topics”). 
Among the 109 topics, eight (7%) had a statistically 
significant sex-treatment interaction. The 109 topics 
included 311 randomized controlled trials (162 with 
both sexes, 46 with males only, 103 with females only). 
Of the 162 individual randomized controlled trials that 
included both sexes, 15 (9%) had a statistically 
significant sex-treatment interaction. Of four topics 
where the first published randomized controlled trial 
had a statistically significant sex-treatment interaction, 
no meta-analyses that included other randomized 
controlled trials retained the statistical significance and 
no meta-analyses showed statistical significance when 
data from the first published randomized controlled 
trial were excluded. Of the eight statistically significant 
sex-treatment interactions from the overall analyses, 
only three were discussed by the CDSR reviewers for a 
potential impact on different clinical management for 
males compared with females. None of these topics 
had a sex-treatment interaction that influenced 
treatment recommendations in recent guidelines. 
UpToDate, an online physician-authored clinical 
decision support resource, suggested differential 
management of men and women for one of these 
sex-treatment interactions.
COnClusiOn
Statistically significant sex-treatment interactions are 
only slightly more frequent than what would be 
expected by chance and there is little evidence of 
subsequent corroboration or clinical relevance of 
sex-treatment interactions.
Introduction
Subgroup analyses in randomized controlled trials are 
commonly used to determine whether treatment effects 
vary across certain patient characteristics, such as 
whether an effect is different between males and 
females.1-5  It has been proposed that results from these 
analyses can be used to tailor patient care (“stratified 
medicine” and “precision medicine”).6-8  In particular, 
male and female subgroups are often compared for 
their responses to a broad range of interventions owing 
to differences that might exist between the sexes in 
physiology, pharmacokinetics, and pharmacodynam-
ics.9-12  For example, it is speculated that women might 
respond differently from men to some drugs and might 
have more adverse events in response to certain 
drugs.9-15 Though there is substantial interest about sex 
differences in treatment effects, and stratification by 
sex is common in clinical trials, relatively little is known 
about how often subgroup differences are valid and 
how frequently the findings of sex based subgroups go 
on to affect specific clinical practice. Clearly, if sub-
group differences are such that only men or only 
women deserve treatment with some intervention, this 
would have major implications for clinical practice.
There are many reasons to suspect a lack of validity 
in subgroup claims. Trials often perform numerous sub-
group analyses without correcting for multiple testing, 
thereby increasing the probability of false positive 
claims of a true difference between subgroups.1 16 17  Fur-
thermore, subgroup analyses are often not prespeci-
fied, which can increase the reporting of spurious 
findings.4 18-20  Even when an analysis plan is prespeci-
fied for subgroups in randomized controlled trials, 
more than 90% of the trials deviate from the protocol.18
WhAT IS AlReAdy knoWn on ThIS TopIC
Subgroup analyses are often performed and differential treatment effects are 
sometimes claimed among patient subgroups
Subgroup differences might offer insights on how to optimize individualized 
treatment, but they might also be spurious
There is a lot of interest about sex differences in treatment effects, and stratification 
by sex is common in clinical trials
WhAT ThIS STudy AddS
An assessment of 109 topics shows that significant sex-treatment interactions from 
Cochrane reviews are only slightly more common than what would be expected by 
chance
Meta-analyses rarely corroborate sex based subgroup findings from individual 
randomized trials
Statistically significant sex-treatment interactions typically have limited biological 
plausibility or clinical significance
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Considering the likelihood of spurious findings from 
subgroup testing, external replication studies that 
would contribute evidence to meta-analyses are neces-
sary to determine the validity of subgroup differences.20 
Though there is evidence that pure replication studies 
in the biomedical literature are rare,21  it is unclear how 
often subgroup findings are externally corroborated by 
pooled evidence from meta-analyses. Lastly, formal 
tests of statistical interaction need to be done systemat-
ically to assess initial claims of subgroup differences 
and their corroboration.4 20 22 23 We used data from the 
Cochrane Database of Systematic Reviews (CDSR) to 
evaluate the frequency, validity, and clinical impact of 
sex related subgroup differences for diverse outcomes 
across a large number of interventions assessed in ran-
domized controlled trials.
Methods
See the supplementary file for the study protocol.
identification of relevant meta-analyses
To identify the search terms necessary to locate sex 
based subgroup analyses in the forest plots of the 
meta-analyses published in the CDSR, we performed a 
pilot PubMed search using the terms: “The Cochrane 
database of systematic reviews”[Journal] AND (gender 
OR sex OR male OR female OR men OR women OR man 
OR woman AND subgroup*)”. Two independent review-
ers (JDW, JFT) then selected and reviewed a random 
sample of articles in full text to establish the most com-
mon terminology used for sex or gender subgroup anal-
yses in the data and analysis section and the forest plots 
of Cochrane meta-analyses. Cochrane representatives 
then performed an automated search on 30 March 2016 
for the terms “gender” OR “sex” OR “men” OR “women” 
OR “male” OR “female” in the “Data and Analysis” sec-
tion of Cochrane reviews published between issue 1, 
1995, and issue 2, 2016, and extracted the review group, 
title, and CD number for all of the search results.
article and forest plot screening
Three reviewers (JDW, JFT, PGS) screened all of the arti-
cles located by the CDSR search to identify those that 
contained at least one sex based subgroup analysis. 
First, we excluded duplicate studies, withdrawn stud-
ies, and studies where the title and abstract indicated a 
clear sex specific outcome (eg, menopause for women). 
Next they examined all forest plots from the remaining 
articles to determine if they contained a sex based sub-
group analysis, or any of the aforementioned search 
terms in their title, because reviews might present a sex 
based subgroup analysis across separate forest plots for 
men and women rather than a single subanalysis 
within the same forest plot. When a forest plot for males 
matched a forest plot for females on intervention and 
outcome within a given study, we considered the pair of 
forest plots as a single sex based subgroup analysis. We 
excluded forest plots with data from non-randomized 
controlled trials (eg, quasirandomized, observational 
studies). Two reviewers (JDW, JPAI) arbitrated all poten-
tial discrepancies.
Data extraction
For all eligible forest plots that passed both initial 
stages of screening, one reviewer (JDW) manually 
extracted several characteristics: study population; 
treatment interventions compared; outcome; number 
of randomized controlled trials on men overall, men 
only, women overall, women only, and both men and 
women; total sample size of individual randomized 
controlled trials (for men, women, and both sepa-
rately); effect measure used in each separate analysis 
(eg, odds ratio, risk ratio, risk difference, rate ratio, 
mean difference, standardized mean difference, Peto 
odds ratio); methods used for data synthesis (eg, fixed 
effects (Mantel-Haenszel, inverse variance, Peto) or ran-
dom effects (Mantel-Haenszel, inverse variance)); num-
ber of randomized controlled trials that included both 
men and women (trials with separate data on each sex); 
and, when available, P value from the χ2 test for sub-
group differences. Two additional independent review-
ers (PGS, JFT) checked the extracted data for accuracy.
On compiling the eligible evidence, we came across 
instances when a single CDSR meta-analysis might pres-
ent multiple forest plots with similar outcomes for the 
same intervention. Therefore to avoid redundancy we 
devised criteria to prevent the same data from being 
included across multiple analyses. When a single 
meta-analysis presented forest plots evaluating 
sex-treatment interactions with identical or nearly iden-
tical outcomes on the same intervention, we only 
selected one comparison (eg, frequency of drinking 
measured as quantity of drinking in grams per week, 
frequency of drinking measured as the number days 
drinking per week, and intensity of drinking measured 
as the number of grams per drinking day were deemed 
to be nearly identical and thus correlated outcomes24 ). 
When the population, outcome, or eligibility criteria for 
one eligible analysis was a subset of the population, out-
come, or eligibility criteria from a separate forest plot 
representing a similar yet broader meta-analysis, we 
selected the primary analysis described in the text of the 
article (eg, we selected the outcome of “incidence lung 
cancer” because it was a primary outcome and a subset 
of “incidence of all cancers,” which was excluded25). If 
there was no clear primary analysis, multiple outcomes 
were considered primary analyses, or primary analyses 
were not specified in the text, we retained the analysis 
with the most data (larger number of trials, or, when 
there was a tie, smaller variance in the summary effect). 
In cases where a subgroup analysis was presented for 
the same intervention but with multiple distinct out-
comes, we kept all of the intervention-outcome pairs, 
but made note of how many outcomes there were for 
each comparison. All eligible intervention-outcome 
analyses (ie, at the forest plot level rather than the arti-
cle level) will hereafter be referred to as “topics.”
As suggested during peer review of our work, we also 
give the proportion of statistically significant sex- 
treatment interactions considering only one topic in 
each CDSR review with relevant data and the propor-
tion of statistically significant sex-treatment interac-
tions considering only one outcome for each 
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comparison in each CDSR review, when a review had 
data on multiple different comparisons of interven-
tions. When multiple topics still existed for the same 
review or comparison in our sample, we further selected 
the one with the largest available sample size (or, in the 
case of ties, we selected the one with the largest number 
of events or the smallest variance in the summary 
effects, if counts were not provided). These analyses 
avoid the potential lack of independence among some 
topics and use the topics with maximal power to detect 
subgroup differences.
statistical analysis
RevMan (version 5.4) was used to recreate the forest 
plots identified by our search and to test the sex-treat-
ment interaction using the same meta-analysis meth-
ods as those presented in the original review in the 
CDSR. Because many of the eligible forest plots con-
tained randomized controlled trials performed on one 
sex, we recreated the forest plots and evaluated the 
sex-treatment interaction including only the random-
ized controlled trials that include data for both men and 
women. The sex-treatment interaction was also evalu-
ated for each individual randomized controlled trial 
with data for both sexes.
We used our best judgment to determine whether 
each individual study from a forest plot represented a 
single randomized controlled trial or information pooled 
from multiple randomized controlled trials. When a for-
est plot only provided pre-pooled information from mul-
tiple trials (eg, summary hazard ratios based on 
individual participant data from multiple trials), we only 
calculated the overall sex-treatment interaction for the 
pooled data. In cases where the entries in a forest plot 
did not include a study date, we checked the reference 
section of the CDSR review to determine whether multi-
ple studies had been pre-pooled or whether a study date 
could be established. We treated multiple pre-pooled 
entries without a study date as “grouped studies” and 
tested the sex-treatment interaction for the grouped 
entries. When two or more randomized controlled trials 
from the same topic were published in the same journal 
issue, or data from multiple randomized controlled tri-
als were grouped in a previous article, we counted the 
trials as one trial. When multiple randomized controlled 
trials from the same topic were published in the same 
year, we counted them together as representing the first 
trial evidence, since the window of opportunity for cor-
roboration was too short.
For each topic we recorded whether a nominally sta-
tistically significant (P<0.05) sex-treatment interaction 
was seen in the overall meta-analyses and in the 
meta-analysis based only on the randomized controlled 
trials that included data for both men and women. Fur-
thermore, we assessed whether the first published ran-
domized controlled trial included in a meta-analysis had 
a significant sex-treatment interaction and whether this 
difference occurred in any other randomized controlled 
trial with data on both sexes. We then recorded whether 
the significant sex-treatment interaction that occurred 
in the first published randomized controlled trial, or in 
any individual randomized controlled trial, was corrob-
orated by the summary of data from all randomized con-
trolled trials in the same meta-analysis. We were 
particularly interested in the first published randomized 
controlled trial because this was likely the first time that 
a certain sex-treatment interaction was proposed. It is of 
interest to note whether individual subsequent random-
ized controlled trials corroborate the hypotheses pro-
posed by the first published randomized controlled trial. 
Furthermore, if the first published randomized con-
trolled trial had a statistically significant sex-treatment 
interaction it might be more likely that subsequent ran-
domized controlled trials performed the same analyses.
To determine whether standardization of the forest 
plots affected the interpretation of the results, we recre-
ated all of the forest plots using a random effects (Der-
Simonian and Laird) model with standard effect 
measures. The DerSimonian and Laird random effects 
model allows for treatment effects to vary across studies 
and is often used for clinical trials.26 27 We selected the 
risk ratio and the mean difference because they were 
the most commonly reported effect measures for binary 
and continuous data, respectively. Hazard ratios and 
rate ratios were not transformed.
We noted how many P values from the test for sub-
group differences were less than 0.05. As a sensitivity 
analysis for significant sex-treatment interactions, we 
also used the Hartung-Knapp-Sidik-Jonkman method 
for random effects meta-analysis in R using the metafor 
package,28  because this method generates lower mean 
error rates than the standard DerSimonian-Laird 
method.29
analysis of clinical relevance of significant sex-
treatment interactions
For statistically significant (P<0.05) sex-treatment inter-
actions, two independent investigators (JDW, PGS) 
extracted the comparison, population, outcome, over-
all effect size, effect size for males, effect size for 
females, number of randomized controlled trials, num-
ber of randomized controlled trials that included both 
sexes, and interaction P value. We also examined the 
full text of the respective CDSR review and noted those 
presenting evidence of biological plausibility and clini-
cal relevance. As a non-prespecified objective, we then 
subjectively considered the biological plausibility and 
the potential clinical relevance of the sex-treatment 
effect, particularly whether it might translate to a differ-
ence in clinical management between subgroups. For 
eligible topics with biological plausibility and the 
potential for clinical relevance, we performed non-sys-
tematic searches and scrutinized recent guidelines for 
evidence suggesting differential clinical management 
based on the sex-treatment effects.
analysis of general subgroup reporting practices 
within the CDsr
Finally, we used PubMed to identify and screen a random 
sample of 100 reviews drawn from the CDSR (“the 
Cochrane Database of Systematic Reviews”[Journal], 
search performed on 30 May 2016). This was done to 
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describe general sex related subgroup reporting practices 
by the CDSR and to account for the possibility that sub-
group analyses might be planned in the data and analy-
ses section, but not conducted, reported, or visualized as 
a forest plot. We excluded reviews that were withdrawn, 
included outcomes that only pertained to one specific 
sex, and did not list randomized trials as one of the selec-
tion criteria. Since all topics with a sex-treatment interac-
tion from our Cochrane search came from forest plots that 
included only randomized trials, we made note of the 
reviews with data from only randomized trials in the for-
est plots. We included studies where some of the primary 
outcomes focused exclusively on females if any of the out-
comes in the review also pertained to neonates or infants, 
since both sexes could be represented.
As a non-prespecified outcome suggested during peer 
review, we also investigated whether CDSR reviews that 
report some eligible sex subgroup data do this only for 
a subset of the relevant trials, while they report infor-
mation without stratification by sex on all trials. We 
examined this possibility by focusing on one topic per 
review (selected as described) and estimating what pro-
portion of total sample size was also represented in the 
sex subgroup analyses.
Patient involvement
No patients were involved in the development of the 
research question, development of outcome measures, 
design, or conduct of this study. There are no plans to 
involve patients in the dissemination of the results of 
this study.
Results
search results
The search performed on the CDSR identified 1711 arti-
cles for review at the title and abstract level. Of these 
1711 reviews, 322 were duplicate publications, 215 had 
outcomes that pertained only to females, 22 had out-
comes that pertained only to males, and 11 were reviews 
that had been withdrawn, leaving 1141 articles requir-
ing visual inspection of all forest plots. Out of these 1141 
articles, 41 included data from randomized controlled 
trials that had sex based subgroups as determined by 
screening of the forest plots (fig 1). A total of 23 (56%) of 
the 41 reviews had more than one eligible topic, and 
there were a total of 109 eligible topics with sex based 
subgroup data.
Characteristics of included meta-analyses
Supplementary table 1 shows the characteristics of the 
reviews with sex based subgroup information con-
tained in the forest plots. The 109 topics included a total 
of 311 trials (162 with data on both men and women, 46 
with data only on men, and 103 with data only on 
women).
The median total sample size for each topic was 923 
(interquartile range 225-2807), with 306 males (110-
1600) and 483 females (115-1481). The median number 
of randomized controlled trials on males and females, 
among the 106 topics without individual patient data, 
were the same (n=1, interquartile range 1-2) (three topics 
reported hazard ratios based on pooled individual 
patient data, where information was not available at 
the level of single randomized controlled trials).
The most frequently reported effect measures among 
the 109 topics were the mean difference or mean change 
difference (n=42, 39%), risk ratio (n=25, 23%), and Peto 
odds ratio (n=21, 19%). Most analyses used inverse vari-
ance weighting (n=48, 44%) or Mantel-Haenszel methods 
(n=37, 34%). Just under half (n=54, 50%) of the 109 topics 
included only a single randomized controlled trial provid-
ing data for both males and females, and another four 
(4%) topics had only one randomized controlled trial with 
exclusively males and one with exclusively females.
frequency of significant sex-treatment interactions
Since the results from the non-standardized and stan-
dardized forest plots were almost identical, we pre-
sented the results from the standardized calculations, 
using a random effects (inverse variance) model for a 
risk ratio or mean difference effect measure. When we 
recalculated the sex-treatment interactions for the top-
ics with more than one randomized controlled trial 
using the Hartung-Knapp-Sidik-Jonkman method, the 
two eligible topics remained statistically significant.
Among the 109 topics, eight (7%) had a statistically 
significant sex-treatment interaction. When we recre-
ated the forest plots using only the topics with at least 
one randomized controlled trial with data for both men 
and women or those with individual participant data, 
six (6%) out of 96 had a significant sex-treatment inter-
action. Overall, 162 individual randomized controlled 
trials could be tested for a sex-treatment interaction. Of 
these, 15 (9%) had a statistically significant sex-treat-
ment interaction.
When considering only the 39 topics with multiple 
randomized controlled trials and at least one trial with 
CDSR search results with gender, sex, men, women,
male, or female in data and analysis section (n=1711)
Non-duplicate/latest versions of reviews or updates screened
at title and abstract level for sex specic reviews (n=1389)
Figures reviewed from remaining articles (n=1141)
Eligible articles with at least one sex based
subgroup analysis in forest plots with data
from randomized controlled trials only (n=42)
Eligible articles with at least one sex based
subgroup analysis in forest plots with data
from randomized controlled trials only (n=41)
Multiple publication versions (n=322)
Withdrawn in June 2016 (n=1)
Excluded (n=248):
  Based on title and abstract (n=237):
    Men (n=22)
    Women (n=215)
  Withdrawn (n=11)
fig 1 | flow diagram of included studies. CDsr=Cochrane 
Database of systematic reviews
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data for both men and women (eg, one randomized con-
trolled trial with data for men and women, one with 
data for men only, and one with data for females only), 
three (8%) had significant sex-treatment interactions. 
When the 39 individual randomized controlled trials 
with data on only one sex were excluded and only the 
trials with data for both men and women were included, 
four (10.3%) had a significant sex-treatment interaction. 
Two of the topics had only one randomized controlled 
trial with data for both males and females, and one of 
these topics had two randomized controlled trials that 
were published in the same edition of a journal.30
Even when we selected only one topic with sex sub-
group data in each CDSR review, there were only four 
(10%, 4/41) statistically significant sex-treatment inter-
actions. When we allowed for multiple comparisons 
from each CDSR review, with only one outcome selected 
for each comparison, there were seven (11%, 7/61) statis-
tically significant sex-treatment interactions.
Table 1 summarizes the proportion of statistically sig-
nificant sex-treatment interactions when different eligi-
bility criteria are used to select eligible topics.
Corroboration of sex-treatment interactions by 
subsequent trials
Among the 39 topics with more than one randomized 
controlled trial and at least one randomized controlled 
trial with data for both men and women, 106 trials (or 
grouping of randomized controlled trials) could be 
tested for a sex-treatment interaction. Of these 106 tri-
als, 12 (11%) had a statistically significant sex-treatment 
interaction. Four of these 12 were the first published 
trial in the respective study. Of these four randomized 
controlled trials, three were from topics with more than 
one randomized controlled trial with data for both men 
and women (n=2 had only two randomized controlled 
trials with data for both men and women and n=1 had 
four randomized controlled trials with data for both 
men and women). Two of the statistically significant 
sex-treatment interactions from the first published ran-
domized controlled trial were tested at a later date by 
randomized controlled trials with at least one of the 
same authors from the first published randomized con-
trolled trial. None of the subsequent individual ran-
domized controlled trials with data for both men and 
women corroborated the statistically significant 
sex-treatment interaction from the first published ran-
domized controlled trial. For the five studies attempting 
to corroborate the statistically significant sex-treatment 
interaction from the first published randomized 
 controlled trial from their respective review, the median 
sample size was 886 (interquartile range 734-1810).
When the four forest plots were recreated excluding 
the first randomized controlled trial with a statistically 
significant sex-treatment interaction, none of the 
remaining randomized controlled trials validated the 
statistically significant results. Supplementary table 2 
provides additional information about the four statisti-
cally significant sex-treatment interactions from the 
first published randomized controlled trials that were 
not corroborated by cumulative meta-analyzed data, 
among the topics with more than one randomized con-
trolled trial with data for both men and women.
Clinical relevance
The eight statistically significant sex-treatment interac-
tions (table 2 ) did not present a consistent pattern in 
populations, disease of interest, interventions, or out-
comes.25 30-36  Three of the eight topics  contained data 
from only a single randomized controlled trial. Five of 
the eight topics had effect sizes in the same direction for 
males and females. In four of the eight topics, the 
reviews explicitly stated that they planned to investi-
gate gender or sex subgroups. There were two topics31 35 
where both biological rationale and clinical relevance 
were discussed in the review, and one topic34  where 
only clinical relevance was discussed. There was one 
topic where the authors suggested a potential for bio-
logical rationale, but noted that no conclusions should 
be made based on one study.36  However, none of these 
three topics with a discussion on clinical relevance 
found sex-treatment interactions that were consistent 
with recent guidelines. UpToDate, a physician-authored 
clinical decision online support resource, suggested dif-
ferential management for men and women for one of 
the topics (perform surgery in men but not in women 
with symptomatic 50-69% carotid stenosis).37
For example, in the topic where systematic screening 
was compared with routine practice for the primary out-
come of detection of new cases of atrial fibrillation 
among patients aged more than 40, the authors included 
some discussion of both biological rationale and clinical 
table 1 | summary results for proportion of statistically significant sex-treatment interactions based on different eligible 
criteria
eligibility criteria
no of topics 
(no of trials)
no (%) of statistically 
significant sex-treatment 
interactions
All 109 (311) 8/109 (7)
Only topics with data for both men and women 96 (162) 6/96 (6)
Only topics with >1 RCT and at least one RCT with data for both men and women* 39 (209) 3/39 (8)
As above, but excluding RCTs with data on only one sex* 39 (106) 4/39 (10)
One topic per review (most inclusive topic with the most data) 41† (164) 4/41 (10)
One topic per treatment comparison (most inclusive topic with the most data) 61‡ (194) 7/61 (11)
RCT=randomized controlled trial.
*Excluding topics based on individual patient data, where trial level information was not provided.
†One topic only had individual participant data and no trial level information.
‡Two topics only had individual participant data and no trial level information.
doi: 10.1136/bmj.i5826 | BMJ 2016;355:i5826 | the bmj
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significance for the management of men versus women. 
The authors noted that men are 1.5 times more likely than 
women to develop atrial fibrillation, which could make 
screening more effective in men.38  Furthermore, the 
review notes that there could be differences in the uptake 
of screening programs among men and women, which 
could ultimately impact clinical outcomes. Overall, the 
authors noted that the observed difference could be a 
result of a higher prevalence of atrial fibrillation among 
men and a greater rate of participation.35  However, the 
results are based on a single randomized controlled trial, 
and additional evidence is necessary. The 2014 guideline 
from the American Heart Association/American College 
of Cardiology/Heart Rhythm Society for the management 
of patients with atrial fibrillation does not even mention 
screening,39  and the 2012 focused update of the Euro-
pean Society of Cardiology guidelines for the manage-
ment of atrial fibrillation only recommends opportunistic 
screening in patients aged 65 years and older, and it does 
not differentiate between men and women.40  UpToDate 
recommends against screening.41
In another example, a statistically significant sub-
group finding was seen for surgery (carotid endarterec-
tomy) compared with no surgery in patients with recent 
symptomatic carotid stenosis for the primary outcome 
of five year cumulative risk of ipsilateral carotid isch-
emic stroke or any stroke or death within 30 days.31  The 
authors of the review suggest that sex is a clinically 
important effect modifier given the lower risk of isch-
emic stroke during medical treatment and higher oper-
ative risk in women.31  Other authors have offered a 
mechanistic explanation as to why anatomical differ-
ences could affect carotid endarterectomy.42  Although 
the most recent American Heart Association/American 
Stroke Association guidelines for the prevention of 
stroke do not make a distinction between the treatment 
of men and women,43  UpToDate suggests differential 
management for men and women with recently symp-
tomatic carotid stenosis of 50-69%.37
Finally, in the topic where risperidone was compared 
with olanzapine for the adverse effect of change in pro-
lactin levels from baseline, the authors included a dis-
cussion about clinical significance.34  Antipsychotic 
drug treatments are known to cause increases in plasma 
prolactin levels, and for women, hyperprolactinemia 
could be related to severe menstrual disorders.44 
Although the review does not discuss any biological 
rationale, the authors state that clinicians might want 
to consider the different tolerability profiles of risperi-
done and olanzapine.34
general sex based subgroup reporting practices 
within the CDsr
Among the first 100 randomly selected reviews drawn 
from the CDSR that did not include reviews that had 
been withdrawn, reviews with outcomes that pertained 
to one specific sex, and reviews that did not list ran-
domized trials as one of the selection criteria, 12 (12%) 
did not identify any studies. Among the 88 remaining 
reviews, forest plots in 83 (94%) only included data 
from randomized trials.t
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Among these 83 reviews, three (4%) mentioned sex 
subgroup analyses under the data and analysis section 
and did not include any sex subgroup testing in the 
results or in a forest plot. Two reviews stated that the 
subgroup analyses could not be performed45 46  and one 
review47 separated trials with less than 45% female par-
ticipants compared with other trials.
Among the 83 reviews, only one48 had a forest plot 
with sex based subgroup data from individual patient 
data. Since this review did not discuss any sex or gender 
subgroup analyses in the data and analysis section, it 
was not captured by our search. The post hoc sex-treat-
ment interaction reported was borderline statistically 
significant (P=0.049) and the authors stated that there 
was some suggestion of men benefitting more on a rela-
tive scale than women from chemotherapy for the out-
come of survival.
Finally, we compared the total sample size in the sex 
stratified forest plots compared with the non-stratified 
analyses for the same comparison and outcome in the 
41 topics (selecting the one with more evidence when 
multiple topics existed in the same CDSR review). We 
were able to gather information about sample size for 
40 of the 41 topics. We found that the average propor-
tion of the total sample size that was included in the 
subgroup analyses was 78% (interquartile range 
53-100%). The four topics that had statistically signifi-
cant sex interactions were based on 11%, 55%, 100%, 
and 100% of the respective total sample size for the 
same comparison and outcome.
discussion
Our empirical evaluation of statistically significant 
sex-treatment interactions from the CDSR revealed only 
eight (7%) statistically significant sex-treatment inter-
actions among 109 topics. This is not much beyond 
what would be expected by chance alone. With only 
eight statistically significant interactions, it is likely 
that the number of false positives outnumbered the 
number of true positives. Also, certain reviews had 
more than one topic, which could lead to an overlap of 
topics with non-independent data. However, even when 
we selected only one topic for each review or allowed 
for multiple comparisons with one outcome per review, 
the statistically significant sex-treatment interactions 
would still be uncommon (4/41 (10%) and 7/61 (12%), 
respectively), not far from what is expected from 
chance. None of the sporadically observed statistically 
significant sex-treatment interactions has resulted in a 
clear difference in clinical management for men com-
pared with women.
Many of the assessments of sex related subgroup dif-
ferences were based on a single trial for each topic. 
Thus, even when a significant difference was found, 
there was no evidence of independent corroboration. 
Previous research suggests that replication studies are 
rare,21  and it is common for clinical topics of interest to 
have evidence that comes from only a single trial.49 
When multiple trials were published on the same topic, 
we found that sex based differences in the first trial 
were not corroborated by the meta-analysis combining 
the data from all relevant trials. Furthermore, they were 
never validated by the meta-analysis excluding the data 
from the first trial with a statistically significant 
sex-treatment interaction.
The importance of corroborating subgroup claims is 
illustrated by an example from one topic that we 
assessed. In a meta-analysis comparing home based 
with clinic based specimen collection in the manage-
ment of Chlamydia trachomatis and Neisseria gonor-
rhoeae infections among sexually active people for the 
outcome of uptake, there was no overall sex-treatment 
interaction based on the two randomized controlled tri-
als that included data for both men and women.50 Both 
trials had found statistically significant sex-treatment 
interactions, but the stratified results were in opposite 
directions. This serves as an important reminder that 
healthcare providers should exercise caution and clini-
cal judgment when interpreting subgroup results from 
a single study. As our study shows, sex based subgroup 
findings are rarely corroborated at the meta-analysis 
level and they rarely are included in clinical guidelines 
or recommendations.
limitations of this study
Our study has some limitations. First, although we 
believe we have captured the majority of the sex based 
subgroup analyses available in the CDSR, the number 
of reviews we found with these analyses was relatively 
small, and many of these analyses included only a sin-
gle randomized controlled trial with data for men and 
women. The evidence for many topics is therefore 
underpowered to detect modest differences in effect 
sizes in men compared with women. However, many 
modest differences in effect sizes are unlikely to be clin-
ically relevant. Another limitation is that it is possible 
that the authors of the CDSR reviews sometimes chose 
to simply present sex subgroup data for descriptive pur-
poses or because it was easier to extract stratified data 
(eg, if mean differences were reported separately for 
men and women in the original randomized controlled 
trial), and they were not interested in testing or report-
ing a sex-treatment interaction. It is also possible that 
CDSR reviewers may not have been able to perform sex 
based subgroup analyses owing to selective reporting in 
individual randomized controlled trials. When individ-
ual trials choose not to present certain data, meta-anal-
yses are prevented from pooling data from all available 
sources and some differences might be masked. In our 
survey we assumed that all forest plots with data strati-
fied by sex were subgroup analyses. Furthermore, we 
did not examine sex based subgroup analyses that were 
not presented in forest plots of the CDSR articles that we 
screened. To deal with the possibility that some sub-
group analyses might have been planned in a CDSR 
review, but not ultimately performed, reported in the 
text, or depicted as a forest plot, we took a random sam-
ple of reviews from Cochrane reviews in PubMed to 
evaluate subgroup practices in Cochrane reviews. In the 
random sample, all sex or gender subgroup analyses 
that were proposed in the data analysis section of the 
text were not included in the forest plots and the 
doi: 10.1136/bmj.i5826 | BMJ 2016;355:i5826 | the bmj
RESEARCH
8
authors stated in the results or discussion sections that 
subgroup analyses could not be performed. Among the 
88 reviews with forest plots that only included data 
from randomized trials, there was only one study with a 
sex-treatment interaction in a forest plot, and our 
Cochrane search did not identify this meta-analysis. It 
is possible that several dozen such reviews might have 
been missed by our search. However, it is unlikely that 
sex based analyses that were not clearly referenced in 
the data and analysis section, and thus missed by our 
automatic Cochrane search, would have higher chances 
of being corroborated. It is possible that several 
non-statistically significant sex-treatment interactions 
are not being reported in the forest plots of the Cochrane 
reviews. Furthermore, it could be argued that individual 
trials might be more likely to present stratified results if 
the sex-treatment interaction is statistically significant. 
This could lead to more statistically significant 
sex-treatment interactions based on pooled data in the 
meta-analyses. It is also possible that only a subset of 
trials investigate sex subgroup differences, leading to a 
reduced power to detect any true subgroup differences. 
However, we found that this was not a likely explana-
tion, because in most circumstances when sex-treat-
ment interactions had been assessed in eligible CDSR 
meta-analyses, data had been included by all or almost 
all relevant trials assessing the comparison of interest. 
Among the 40 eligible topics, we found that the average 
proportion of total evidence available for each outcome 
that was included in the subgroup analyses was 78%. 
Lastly, in some cases, individual meta-analyses had 
more than one topic and these might not have been 
independent. However, analyses restricting to data 
where such dependence was not an issue showed 
largely similar results.
implications for researchers and users of 
information from meta-analyses
Although subgroup analyses might often be reasonable 
to explore possible heterogeneity of treatment effects 
across patient populations or to generate new hypothe-
ses, our study suggests that significant sex-treatment 
interactions, on the basis of data from single random-
ized controlled trials and meta-analyses, rarely occur 
beyond what would be expected by chance. It has been 
repeatedly shown that subgroup claims on relative 
effects are often not credible,20  and we have provided 
additional evidence of the lack of corroboration and 
validation of significant sex-treatment interactions 
from individual randomized controlled trials by subse-
quent studies and meta-analyses. We should acknowl-
edge that men and women might still have different 
absolute risks of outcomes of interest, and thus sex 
might sometimes need to be considered as a prognostic 
variable, even in the presence of equal treatment effects 
on the relative scale.6 51  Both prognostic and predictive 
factors define the possible benefits of an interven-
tion.51-54 However, subgroup analyses from meta-analy-
ses can lead to spurious findings.
The US National Institutes of Health has introduced a 
new policy that asks applicants to “explain how 
 relevant biological variables, such as sex, are factored 
into research designs and analyses for studies in verte-
brate animals and humans.”55 56  It is possible that as a 
result of this policy, more investigators will routinely 
perform exploratory sex subgroup analyses without 
considering biological or clinical relevance. However, 
the NIH also states that authors should describe how 
sex might influence the research questions being stud-
ied and that authors should perform a review of the rel-
evant literature. If evidence of differences between men 
and women in previous studies is found by authors, it 
would then provide justification to consider sex in the 
research design and data analysis.55 56  It remains to be 
seen whether this policy will improve the conduct and 
documentation of sex subgroup analyses in trials with-
out generating a greater burden of false positive signals 
in subgroup differences. The Cochrane Sex/Gender 
Methods Group, which was established in 2005, also 
promotes the integration of sex or gender analysis in 
meta-analyses. A sex and gender in systematic review 
planning tool exists to help reviewers plan and inter-
pret their results. The planning tool outlines that “ques-
tions about possible sex and gender differences should 
be asked and the particular relevance determined or 
ruled out.”57  Furthermore, authors are told to consider 
any previous evidence and whether interventions are 
likely to affect men and women differently.57 In our sam-
ple we found little evidence of Cochrane reviews clearly 
justifying all sex based subgroup analyses. Our experi-
ence also suggests that individual Cochrane meta-anal-
yses often perform multiple subgroup analyses for 
similar treatments or outcomes.
Individual randomized controlled trials and 
Cochrane reviews should clearly justify all sex based 
and other subgroup analyses performed. Many 
sex-treatment interactions in the forest plots from the 
CDSR were based on data from only one randomized 
controlled trial, and researchers and clinicians should 
view significant sex-treatment interactions from 
Cochrane reviews as exploratory, unless there is sub-
stantial evidence of corroboration, biological plausibil-
ity, and clinical relevance. We are not arguing that 
researchers should no longer undertake sex based sub-
group analyses in general, but that sex based sub-
groups should be tested only when there is a priori 
credible biological rationale and some expectation for 
clinical relevance. This might not be a common occur-
rence.
Conclusion
Statistically significant sex-treatment interactions from 
Cochrane reviews do not occur much more often than 
what would be expected by chance alone, and 
meta-analyses rarely corroborate individual random-
ized controlled trials with significant sex-treatment 
interactions. Authors, research consumers, and journal 
reviewers and editors should carefully scrutinize the 
credibility of subgroup analyses.58 Isolated sex based 
subgroup analyses are simply hypothesis generating.
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